Search

Your search keyword '"Adams, Kirkwood F Jr"' showing total 159 results
Start Over Author "Adams, Kirkwood F Jr"
159 results on '"Adams, Kirkwood F Jr"'

1. Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF)

Author

Giblin, Erika M., Adams, Kirkwood F., Jr, Hill, Larry, Fonarow, Gregg C., Williams, Fredonia B., Sharma, Puza P., Albert, Nancy M., Butler, Javed, DeVore, Adam D., Duffy, Carol I., Hernandez, Adrian F., McCague, Kevin, Spertus, John A., Thomas, Laine, and Patterson, J. Herbert

Published
2019
Full Text
View/download PDF

4. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial

Author

Teerlink, John R, Felker, G Michael, McMurray, John J V, Solomon, Scott D, Adams, Kirkwood F, Jr, Cleland, John G F, Ezekowitz, Justin A, Goudev, Assen, Macdonald, Peter, Metra, Marco, Mitrovic, Veselin, Ponikowski, Piotr, Serpytis, Pranas, Spinar, Jindrich, Tomcsányi, János, Vandekerckhove, Hans J, Voors, Adriaan A, Monsalvo, Maria Laura, Johnston, James, Malik, Fady I, and Honarpour, Narimon

Published
2016
Full Text
View/download PDF

14. Risk stratification for In-hospital mortality in acutely decompensated heart failure: Classification and regression tree analysis

Author

Fanarow, Gregg C., Adams, Kirkwood F., Jr., Abraham, William T., Yancy, Clyde W., and Boscardin, W. John

Subjects
Mortality -- United States, Mortality -- Risk factors, Heart failure -- Risk factors
Abstract

A study is conducted to develop a practical user-friendly bedside tool for risk stratification for patients hospitalized with acute decompensated heart failure (ADHF). The results suggest that ADHF patients at low, intermediate and high-risk for in-hospital mortality can be identified using vital sign and laboratory data obtained on hospital admission.

Published
2005

15. Vasopressin: A new target for the treatment of heart failure

Author

Lee, Craig R., Watkins, Michael L., Patterson, J. Herbert, Gattis, Wendy, O'Connor, Christopher M., Gheorghiade, Mihai, and Adams, Kirkwood F., Jr.

Subjects
Cardiology -- Research, Heart failure -- Care and treatment, Vasopressin -- Research, Vasopressin -- Analysis, Health
Published
2003

16. Surrogate end points in heart failure trials

Author

Gheorghiade, Mihai, Adams, Kirkwood F., Jr., Gattis, Wendy A., Teerlink, John R., Orlandi, Cesare, and O'Connor, Christopher M.

Subjects
Heart failure -- Research, Heart failure -- Care and treatment, Clinical trials, Health
Published
2003

20. B-type natriuretic peptide: From bench to bedside

Author

Adams, Kirkwood F., Jr., Mathur, Vandana S., and Gheorghiade, Mihai

Subjects
Natriuretic peptides -- Research, Heart failure -- Research, Heart failure -- Care and treatment, Health
Published
2003

26. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST)

Author

O'Connor, Christopher M., Gattis, Wendy A., Uretsky, Barry F., Adams, Kirkwood F., Jr., McNulty, Steven E., Grossman, Steven H., McKenna, William J., Zannad, Faiez, Swedberg, Karl, Gheorghiade, Mihai, and Califf, Robert M.

Subjects
Heart failure -- Complications, Dobutamine -- Health aspects, Mortality -- Risk factors, Health
Published
1999

32. Relationship of depression to death or hospitalization in patients with heart failure

Author

Sherwood, Andrew, Blumenthal, James A., Trivedi, Ranak, Johnson, Kristy S., O'Connor, Christopher M., Adams, Kirkwood F., Jr., Dupree, Carla Sueta, Waugh, Robert A., Bensimhon, Daniel R., Gaulden, Laura, Christenson, Robert H., Koch, Gary G., and Hinderliter, Alan L.

Subjects
Depression, Mental -- Research, Cardiac patients -- Psychological aspects, Cardiac patients -- Prognosis, Hospital patients -- Psychological aspects, Hospital patients -- Prognosis, Health
Published
2007

35. [beta]-blockers in heart failure: how far have we progressed?

Author

Adams, Kirkwood F., Jr.

Subjects
Cell research -- Social aspects, Cell research -- Reports, Medical research -- Social aspects, Medical research -- Reports, Medicine, Experimental -- Social aspects, Medicine, Experimental -- Reports, Congestive heart failure -- Development and progression, Congestive heart failure -- Drug therapy, Congestive heart failure -- Social aspects, Congestive heart failure -- Reports, Tuberculosis -- Development and progression, Tuberculosis -- Drug therapy, Tuberculosis -- Social aspects, Tuberculosis -- Reports, Apoptosis -- Development and progression, Apoptosis -- Drug therapy, Apoptosis -- Social aspects, Apoptosis -- Reports, Heart attack -- Development and progression, Heart attack -- Drug therapy, Heart attack -- Social aspects, Heart attack -- Reports, Cardiac patients -- Drug therapy, Cardiac patients -- Social aspects, Cardiac patients -- Reports, Practice guidelines (Medicine) -- Social aspects, Practice guidelines (Medicine) -- Reports, Pharmaceutical industry -- Social aspects, Pharmaceutical industry -- Reports, Bisoprolol -- Social aspects, Bisoprolol -- Reports, Heart -- Transplantation, Heart -- Social aspects, Heart -- Reports, Health
Published
2002

43. Blood pressure reactivity to psychological stress is associated with clinical outcomes in patients with heart failure.

Author

Sherwood, Andrew, Hill, LaBarron K., Blumenthal, James A., Jr.Adams, Kirkwood F., Paine, Nicola J., Koch, Gary G., O'Connor, Christopher M., Johnson, Kristy S., Hinderliter, Alan L., Adams, Kirkwood F Jr, and O'Connor, Christopher M

Abstract

Introduction: Cardiovascular (CV) reactivity to psychological stress has been implicated in the development and exacerbation of cardiovascular disease (CVD). Although high CV reactivity traditionally is thought to convey greater risk of CVD, the relationship between reactivity and clinical outcomes is inconsistent and may depend on the patient population under investigation. The present study examined CV reactivity in patients with heart failure (HF) and its potential association with long-term clinical outcomes.Methods: One hundred ninety-nine outpatients diagnosed with HF, with ejection fraction ≤40%, underwent an evaluation of blood pressure (BP) and heart rate reactivity to a laboratory-based simulated public-speaking stressor. Cox proportional hazards regression models were used to examine the prospective association between BP and heart rate reactivity on a combined end point of death or CV hospitalization over a 5-year median follow-up period.Results: Both systolic blood pressure (SBP) and diastolic blood pressure (DBP) reactivity, quantified as continuous variables, were inversely related to risk of death or CV hospitalization (Ps < .01) after controlling for established risk factors, including HF disease severity and etiology. In similar models, heart rate reactivity was unrelated to outcome (P = .12). In models with tertiles of reactivity, high SBP reactivity, compared with intermediate SBP reactivity, was associated with lower risk (hazard ratio [HR] = .498, 95% CI .335-.742, P =.001), whereas low SBP reactivity did not differ from intermediate reactivity. For DBP, high reactivity was marginally associated with lower risk compared with intermediate DBP reactivity (HR = .767, 95% CI .515-1.14, P =.193), whereas low DBP reactivity was associated with greater risk (HR = 1.49, 95% CI 1.027-2.155, P =.0359). No relationship of heart rate reactivity to outcome was identified.Conclusions: For HF patients with reduced ejection fraction, a robust increase in BP evoked by a laboratory-based psychological challenge was associated with lower risk for adverse CVD events and may be a novel and unique marker of left ventricular systolic reserve that is accompanied by a more favorable long-term prognosis. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

45. Reactive hyperemia is associated with adverse clinical outcomes in heart failure.

Author

Paine, Nicola J., Hinderliter, Alan L., Blumenthal, James A., Jr.Adams, Kirkwood F., Sueta, Carla A., Chang, Patricia P., O’Connor, Christopher M., Sherwood, Andrew, Adams, Kirkwood F Jr, and O'Connor, Christopher M

Abstract

Introduction: Impaired endothelial function, as assessed by brachial artery flow-mediated dilation (FMD), is an established risk factor for cardiovascular events. FMD is impaired in heart failure (HF) patients, but less is known about hyperemic brachial artery flow. We investigated the relationship between FMD and hyperemic flow with adverse clinical outcomes in HF patients.Methods: Brachial artery FMD and hyperemic flow were assessed in 156 patients (70.5 % Male; 45.5% Caucasian; mean age (± SD) = 56.2 (±12.4) years) with HF and reduced left ventricular ejection fraction (LVEF). Cox proportional hazard models were used to assess the potential explanatory association of FMD and hyperemic flow with the composite outcome of death or cardiovascular hospitalization over a median 5-year follow-up period.Results: Both FMD and hyperemic flow were negatively correlated with age, but unrelated to sex, race, body mass index, LVEF or N-terminal pro-B-Type natriuretic peptide (NT-ProBNP). Reduced hyperemic flow, but not FMD, was associated with an increased risk of death or cardiac hospitalization after controlling for traditional risk factors.Conclusion: The association of reduced hyperemic flow with increased risk of adverse clinical outcomes suggests that micro-vascular function may be an important prognostic marker in patients with HF. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

46. Relation between dose of loop diuretics and outcomes in a heart failure population: Results of the ESCAPE Trial

Author

Hasselblad, Vic, Stough, Wendy Gattis, Shah, Monica R., Lokhnygina, Yuliya, O'Connor, Christopher M., Califf, Robert M., Adams, Kirkwood F., Gattis Stough, Wendy, and Adams, Kirkwood F Jr

Subjects
DIURETICS, WEIGHT loss, HEART failure, MORTALITY, DRUG therapy, CARDIOTONIC agents, COMPARATIVE studies, DATABASES, FUROSEMIDE, HOSPITAL care, LENGTH of stay in hospitals, KIDNEYS, RESEARCH methodology, MEDICAL cooperation, MEMBRANE proteins, PEPTIDE hormones, RESEARCH, EVALUATION research, RANDOMIZED controlled trials, TREATMENT effectiveness, THERAPEUTICS
Abstract

Background: We examined the relation of maximal in-hospital diuretic dose to weight loss, changes in renal function, and mortality in hospitalised heart failure (HF) patients.Methods: In ESCAPE, 395 patients received diuretics in-hospital. Weight was measured at baseline, discharge, and every other day before discharge. Weight loss was defined as the difference between baseline and last in-hospital weight. Mortality was assessed using a log-logistic model with non-zero background.Results: Median weight loss: 2.8 kg (0.7, 6.1); mean: 3.7 kg (22% of values <0). Weight loss and maximum in-hospital dose were correlated (p=0.0007). Baseline weight, length of stay, and baseline brain natriuretic peptide were significant predictors of weight loss. After adjusting for these, dose was not a significant predictor of weight loss. A strong relation between dose and mortality was seen (p=0.003), especially at >300 mg/day. Dose remained a significant predictor of mortality after adjusting for baseline variables that significantly predicted mortality. Correlation between maximal dose and creatinine level change was not significant (r=0.043; p=0.412)Conclusions: High diuretic doses during HF hospitalisation are associated with increased mortality and poor 6-month outcome. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

48. Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure

Author

Shah, Monica R., Hasselblad, Vic, Stinnett, Sandra S., Kramer, Judith M., Grossman, Steven, Gheorghiade, Mihai, Adams Jr., Kirkwood F., Swedberg, Karl, Califf, Robert M., O'Connor, Christopher M., and Adams, Kirkwood F Jr

Subjects
HEMODYNAMICS, HEART failure, HEART diseases
Abstract

Background: Changes in hemodynamic measures often serve as surrogate end points in efficacy trials for advanced heart failure, although there are few objective data to support this practice.Aims: We compared changes in hemodynamic variables vs. changes in symptoms of decompensated heart failure in patients enrolled in a randomized trial.Methods: We studied 201 patients with New York Heart Association (NYHA) class IIIb or IV heart failure and ejection fraction < or = 25% for > or = 3 months. Patients underwent continuous monitoring by pulmonary-artery catheter during inpatient drug administration. We assessed the relations of changes in hemodynamic variables (baseline minus final measure) to changes at 2 weeks in congestive heart failure symptoms, NYHA class, Yale Dyspnea-Fatigue Index (YDFI) score, and distance achieved in a 6-min walk.Results: No hemodynamic measure significantly predicted either symptom score or NYHA classification. Mean pulmonary artery pressure and pulmonary capillary wedge pressure did show some relation to change in YDFI score in univariable, but not multivariable, analysis. No hemodynamic measure correlated significantly with changes in distance achieved in the 6-min walk test.Conclusion: We noted no significant association between improved hemodynamics and improved symptoms in patients with advanced heart failure. Other measures may need to be evaluated as surrogate end points in future trials. [ABSTRACT FROM AUTHOR]

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results